“Shanghai-Suzhou” Listed: What Does It Still Lack to Become a Top Global Biopharma Cluster?

The competition among global biopharmaceutical industry clusters is intensifying. For a long time, cities like Boston, New York, and London have firmly held the top positions on the world’s life sciences innovation map. Meanwhile, a group of emerging cities is quietly gaining momentum, trying to secure a spot in the next round of industry reshuffling.

In November 2024, MedCity released the “Life Sciences Global Cities Comparison Report 2024,” evaluating and ranking key global life sciences cities. The “Shanghai-Suzhou” cluster ranked ninth globally as a city-industry cluster. As the only representative from a developing country on the list, many questions remain behind the ranking: What exactly separates them from the top tier? What will their next leap rely on?

This article is based on the report, combined with the current industrial evolution and structural comparison of the urban cluster, attempting to unpack the winning logic of global life sciences center cities, clarify Shanghai-Suzhou’s bottlenecks for advancement, and explore their potential and pathways to join the global core circle.

Why Do Boston, New York, and London Secure the Top Three Spots?

The report compares global life sciences cities across five key dimensions: R&D innovation, clinical research environment, talent ecosystem, investment environment, and business environment. Weighted comprehensively, Boston, New York, and London ranked first to third, respectively.

Boston ranks first in both “R&D Innovation” and “Talent Ecosystem.” Massachusetts, one of the smallest U.S. states by area, hosts 122 colleges and universities concentrated in the Boston metro area, building a world-class research ecosystem around top schools like Harvard and MIT. The steady talent pipeline makes it the “standard base” for 18 of the world’s top pharmaceutical companies.

Its geographic constraints drive research institutions, hospitals, and enterprises to cluster tightly, forming a highly synergistic cluster. In contrast, California’s West Coast research base, spreading from San Francisco to San Diego, somewhat dilutes the life sciences cluster synergy. The report suggests that if these were gathered, they might rival Boston.

New York combines advantages in “Investment Environment,” “Business Environment,” and “Clinical Research,” ranking second overall. Thanks to its large clinical trial network and historic research institutions, it ranks first in “Clinical Research Environment.” New York houses the U.S.’s first clinical research center—the Rockefeller Institute, operating since 1910, marking a milestone from lab research to clinical application. Institutions like NYU Langone Medical Center and Sloan-Kettering Cancer Center have strong research capabilities and serve as important testing grounds for innovative therapies.

Moreover, New York hosts the largest number of venture capital firms, frequent financing activities, and a significant number of biopharma unicorns, forming a complete investment loop. Despite these strengths, New York ranks third in R&D innovation and only fifth in the talent ecosystem. Compared to Boston and San Francisco, New York has a smaller labor force and relatively lower quality of life and income potential.

London is similar to New York as a major financial center. It excels in “Business Environment” and “Clinical Research,” benefiting from government support, an international enterprise platform, and a stable financial and regulatory base. It plays a hub role in drug registration, regulatory coordination, and international transactions.

Currently, London’s progress in AI innovation applications consolidates its position. It hosts more life sciences AI and data companies than any other global region, which have attracted over $2.9 billion (￡2.1 billion) in venture capital. Leading research centers like the Alan Turing Institute and Google DeepMind empower drug development, and GSK has established its AI center in London.

These cities share a common trait: they build a comprehensive system around one or two core strengths, covering fundamental research, capital transformation, institutional guarantees, talent supply, and policy support. This gives them sustained leadership and facilitates network spillover effects that radiate to surrounding regions.

Strengths and Weaknesses of China’s Industrial Cluster

As the only developing country cluster in the TOP 10, Shanghai-Suzhou demonstrates China’s rapid rise in life sciences.

Shanghai-Suzhou performs best in the “Investment Environment” dimension, ranking fifth globally. It benefits from frequent foreign direct investment (FDI) projects, competitive investment scale, and numerous venture capital firms, making it the best investment environment city in the Asia-Pacific region.

Additionally, the median amount of seed-stage financing in Shanghai and Shenzhen is very high, with Shenzhen’s financing almost four times that of other overseas cities except Shanghai. Supported by policies and industrial funds, fiscal subsidies, incentives, industrial parks, and incubators have jointly promoted China’s urban investment environment development.

In “R&D Innovation,” Shanghai-Suzhou ranks ninth. China’s research strength is steadily increasing its global visibility. Shanghai-Suzhou excels in international publications and patent ownership, surpassing higher-ranked Paris and Singapore. It also ranks among the world’s top five in international scientific collaboration, behind Boston, San Francisco, New York, and London.

Clinical research environment evaluation is based on the number of medical practice institutions, clinical trials, researchers, early-stage trial enrollment speed, and regulatory process efficiency, with Shanghai-Suzhou ranking sixth.

Notably, in the subdimension of Phase I trial enrollment speed, Shanghai-Suzhou ranks first globally, with Shenzhen and Hong Kong also performing well. This indicates China’s overall early clinical trial efficiency is world-leading, with low costs making it an ideal place for early-stage trials.

However, Shanghai-Suzhou’s shortcomings are also evident in other dimensions:

• Talent ecosystem ranks 12th, with gaps remaining in public education spending, quality of life, and high-level talent income potential compared to top cities.

• Business environment ranks even lower, at 18th, reflecting that Chinese cities are still exploring enterprise valuation systems, international business rule adaptation, and early-stage commercialization mechanisms.

Overall, Shanghai-Suzhou’s profile shows a typical “speed-growth” pattern: strong in individual indicators but lacking a stable, synergistic system structure. This phase allows rapid entry into the global top ranks, but only by addressing talent and business environment weaknesses can it form a sustainable development loop and advance into the world’s top biopharma clusters.

How to Achieve the Next Leap?

Compared horizontally, top global life sciences cities tend to be balanced across five dimensions, while Shanghai-Suzhou shows a “l(fā)ocal peaks + systemic gaps” pattern. The ceiling effect on high scores is much lower than the bucket effect caused by weak areas. In global urban competition, the synergy of multiple indicators often determines development height and stability.

The core to addressing weaknesses lies in dual driving forces of talent system reform and business ecosystem cultivation.

The autonomous cultivation, retention, and incentivization of high-end talent remain bottlenecks for the next breakthrough. On one hand, the “international + local” talent integration mechanism is established; China’s innovation environment can attract overseas scientists, but long-term rooting depends on mutual adaptation between top talent and local industries. On the other hand, cooperation between research and industry in local talent development needs strengthening, enabling researchers to actively participate in industrial application. Moreover, the international recognition of Chinese universities and research institutes is insufficient, affecting some data and rankings on global lists.

Systematic business environment upgrades need to address rule adaptation, valuation systems, and enterprise structure. Currently, Chinese enterprise valuation logic does not align with international standards, lacking mature judgment criteria based on technology routes, market potential, and clinical value on the global market. Additionally, leading local companies have not yet demonstrated large-scale aggregation and integration of small and medium-sized innovative resources and upstream-downstream industrial chains. China lacks globally influential platform enterprises.

It is worth noting that, similar to Germany, China’s overall life sciences industrial strength is not weak but scattered across multiple regional clusters. The global ranking of individual cities might not look impressive. In fact, the Yangtze River Delta region in China is showing preliminary coupling in functional collaboration. Shanghai has advantages in financial capital, talent attraction, and international resource connection, while Suzhou takes the lead in cutting-edge research, industrialization, and manufacturing. If a “city cluster” policy linkage and talent collaboration system can be built, it may form structural advantages similar to the San Francisco Bay Area or the London-Cambridge innovation corridor.

Reference

MedCity. Life Sciences Global Cities Comparison Report 2024. https://medcityhq.com/wp-content/uploads/2024/11/MedCity-Life-Sciences-Global-Cities-Comparison-Report-V7.pdf